Collaboration To Test Efficacy Of Company's Stroke Treatment.
FREMONT, Calif., July 12, 2018 -- Asterias Biotherapeutics, Inc. (NYSE:AST) announced it has entered signed a license agreement with the Regents of the University of California giving the company exclusive rights in all fields of use for a patent family that claims a method of improving recovery in a patient that has suffered an ischemic stroke by administering to the patient stem cell-derived oligodendrocyte progenitor cells.
Pending patent applications that have been filed in the U.S., Canada, China, Japan, Australia, and before the European Patent Organization are included in the exclusive license.
They were filed after AST-OPC1, the company's pluripotent stem cell derived oligodendrocyte progenitor cell product, was tested at UCLA in a rodent model of white matter ischemia in collaboration.
The pending patents are jointly owned by the Regents of The University of California and Asterias, which now has an exclusive license to its share of the IP rights.
The exclusive license agreement is a part of the company's strategy to explore the efficacy of its AST-OPC1 product candidate in other neurological conditions.
AST-OPC1 is in a Phase 1/2a clinical trial in severe spinal cord injury (NCT02302157).
The company also announced that it is testing AST-OPC1 in a second preclinical model of subcortical and white matter ischemia an expert in preclinical models of cerebral ischemia and cell transplantation.
Contact: http: //www.asteriasbiotherapeutics.com
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Preclinical Research|
|Publication:||Stem Cell Business News|
|Date:||Jul 23, 2018|
|Previous Article:||Data Show Neurogenic Compound Improves Cognition And Anxiety In AD Mouse Model.|
|Next Article:||Positive Data Reported In PD Study In Alpha-bynuclein Worm Model.|